PRESS RELEASES

Date	Title
Sep 28, 2023	Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
Sep 25, 2023	Tenapanor for Hyperphosphatemia Approved in Japan
Sep 11, 2023	Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
Sep 8, 2023	Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 7, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
Aug 2, 2023	Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
Jul 27, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
Jul 26, 2023	Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
Jul 20, 2023	Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
Jul 13, 2023	Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com